MBRX Moleculin Biotech Inc
Company Analysis
Latest News
🟢 Moleculin Biotech is trading 5.4% up in pre-market on strong Annamycin cardiac safety findings
Moleculin Biotech is trading $0.60, up 5.4%, in pre-market on September 29, following its September 28 announcement of peer-reviewed Annamycin cardiac safety...
Moleculin Announces Publication of Positive Cardiac Safety Data for Annamycin
Moleculin Biotech announced the publication of a peer-reviewed analysis in "Frontiers in Cardiovascular Medicine" detailing favorable cardiac safety findings...
🔴 Moleculin Biotech is trading 5.25% down with no clear company-specific catalyst
Moleculin Biotech is trading at $0.57, down 5.25%, with no clear company-specific catalyst identified for the September 28 decline. - Its September 25...
🔴 Moleculin Biotech is trading 10.72% down in pre-market
Moleculin Biotech is trading 10.72% lower in pre-market at $0.54, with no clear company-specific catalyst identified for the September 28 decline. - Its...
🔴 Moleculin Biotech is trading 10.72% down in pre-market — no clear company-specific catalyst identified
Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified. - Its latest announcement, on September...
🔴 Moleculin Biotech is trading 10.72% down in pre-market
Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified. - Its latest company announcement, on...
🔴 Moleculin Biotech is trading 10.72% down in pre-market
Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified for the September 28 decline. - The...
🔴 Moleculin Biotech is trading 6.4% down in after-hours trading
Moleculin Biotech is trading 6.4% lower at $0.56 in after-hours trading; no clear company-specific catalyst for the decline was identified. - Shares closed at...
Moleculin Biotech Reports New Preclinical Data for Annamycin in Pancreatic Cancer
Moleculin Biotech, Inc. (MBRX) announced new preclinical data for its lead drug candidate, Annamycin (naxtarubicin), showing its antitumor activity in...
MBRX Rallies 10% Ahead of Pancreatic Cancer Data — But Can a Sub-$12 Million Company Outrun a Delisting Clock?
Shares of Moleculin Biotech surged 10.2% to $0.62 on September 25 as traders positioned ahead of an embargoed cancer-research abstract set to drop at 1:00 p.m....
🟢 Moleculin Biotech is trading 10.25% up today ahead of AACR Annamycin pancreatic-cancer data
Moleculin Biotech is trading 10.25% higher at $0.62 as investors anticipate new Annamycin pancreatic-cancer data at AACR. - The abstract is scheduled for...
🟢 Moleculin Biotech is trading 5% up today ahead of AACR Annamycin pancreatic-cancer data
Moleculin Biotech is trading at $0.60, up +5.15%, ahead of the September 25–28 AACR conference, where new Annamycin pancreatic-cancer data will be...
🟢 Moleculin Biotech is trading 5.59% up today amid likely speculative trading
Moleculin Biotech is trading at $0.56, up 5.59%, with recent volatility and speculative trading appearing more likely than a confirmed catalyst. - The rebound...
🔴 Moleculin Biotech is trading 5.65% down today — with no clear explanation
Moleculin Biotech is trading 5.65% lower at $0.53 after opening-day weakness on September 23, 2026, with no clear explanation for the decline. - The company...
🟢 Moleculin Biotech is trading 6.2% up today after Mexico grants patent for lung-targeted Annamycin technology
Moleculin Biotech is trading up 6.2% now at $0.60 after Mexico granted a patent protecting its lung-targeted liposomal Annamycin technology. - Announced...
🔴 Moleculin Biotech is trading 6.18% down in pre-market with catalyst unclear
Moleculin Biotech is trading 6.18% down at $0.53 in pre-market, with no company-specific announcement identified for September 23, 2026. - Recent coverage...
🟢 Moleculin Biotech is trading 11.57% up today amid biotech sector gains
Moleculin Biotech is trading 11.57% higher at $0.58, mainly as biotech gains and recovery buying follow the prior selloff. - Shares fell 32.71% to $0.52 on...
🟢 Moleculin Biotech is trading 8.59% up today — following sharp 32.71% decline
Moleculin Biotech is trading 8.59% up at $0.56 following a sharp 32.71% decline, with no confirmed company-specific catalyst identified. - It closed at $0.52...
🟢 Moleculin Biotech is trading 5.56% up in pre-market with no company-specific explanation for the rise identified
Moleculin Biotech is trading 5.56% up now at $0.55 after falling sharply to $0.52 on September 21, 2026; no new company-specific announcement explaining the...
Moleculin Faces Nasdaq Exile — Can a Hearing Save a Stock That Already Lost Its Safety Net?
Shares of Moleculin Biotech cratered 29.9% to $0.54 on September 21, 2026, after the clinical-stage drugmaker disclosed that Nasdaq has moved to kick it off...